Compare ALX & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALX | URGN |
|---|---|---|
| Founded | 1928 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1994 | 2016 |
| Metric | ALX | URGN |
|---|---|---|
| Price | $250.06 | $25.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.29 |
| AVG Volume (30 Days) | 27.7K | ★ 704.1K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.50 | N/A |
| Revenue | ★ $213,183,000.00 | $1,128,000.00 |
| Revenue This Year | N/A | $129.09 |
| Revenue Next Year | N/A | $70.96 |
| P/E Ratio | $45.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $198.57 | $3.42 |
| 52 Week High | $260.84 | $30.00 |
| Indicator | ALX | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 75.81 |
| Support Level | $228.61 | $18.55 |
| Resistance Level | $248.67 | $30.00 |
| Average True Range (ATR) | 6.22 | 1.42 |
| MACD | 1.26 | 0.74 |
| Stochastic Oscillator | 81.83 | 82.27 |
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.